Cellestia Enters Clinical Development for its Lead Compound CB-103

Cellestia Enters Clinical Development for its Lead Compound CB-103

14.08.2017 Cellestia enters clinical development for its lead compound CB-103, a new mode of action anticancer drug targeting NOTCH positive cancers, with receiving full approval of its first-in-human Phase I – IIa clinical study.

Read the press release.